Kite Pharma Inc (KITE) - Financial and Strategic SWOT Analysis Review

  • ID: 4281564
  • SWOT Analysis
  • 48 pages
  • GlobalData
  • Kite Pharma Inc
1 of 5

FEATURED COMPANIES

  • Fate Therapeutics Inc
  • Kura Oncology Inc
  • RegenxBio Inc
  • MORE
Kite Pharma Inc (KITE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Kite Pharma Inc (Kite Pharma) is a bio-pharmaceutical company that discovers and develops cancer immunotherapy products. The company concentrates on chimeric antigen receptors (CAR) and T cell receptors (TCR) engineered cell therapies. It offers KTE-C19 in a critical trial for the treatment of refractory, aggressive non-Hodgkin Lymphoma (NHL). Kite Pharma also provides early research and product development services. The company developed engineered autologous T-cell therapy (eACT) technology platform that allows to strengthen patient’s own immune system to target and kill cancer cells. It works in collaboration with various institutes and companies. The company has operational presence in the Netherlands and the US. Kite Pharma is headquartered in Santa Monica, California, the US.

Kite Pharma Inc Key Recent Developments

Aug 08,2017: Kite Reports Second Quarter 2017 Financial Results
Aug 03,2017: Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
Jun 27,2017: Kite Named to the MIT Technology Review’s Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy
May 08,2017: Kite Reports First Quarter Financial Results
Apr 06,2017: Kite wins Clinical Trial Result of the Year award for refractory aggressive B-cell non-Hodgkin lymphoma trial

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Fate Therapeutics Inc
  • Kura Oncology Inc
  • RegenxBio Inc
  • MORE
Section 1 - About the Company
  • Kite Pharma Inc - Key Facts
  • Kite Pharma Inc - Key Employees
  • Kite Pharma Inc - Key Employee Biographies
  • Kite Pharma Inc - Major Products and Services
  • Kite Pharma Inc - History
  • Kite Pharma Inc - Company Statement
  • Kite Pharma Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Kite Pharma Inc - Business Description
  • Kite Pharma Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Kite Pharma Inc - Strengths
  • Kite Pharma Inc - Weaknesses
  • Kite Pharma Inc - Opportunities
  • Kite Pharma Inc - Threats
  • Kite Pharma Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Kite Pharma Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 08, 2017: Kite Reports Second Quarter 2017 Financial Results
  • Aug 03, 2017: Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
  • May 08, 2017: Kite Reports First Quarter Financial Results
  • Apr 04, 2017: Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles
  • Mar 16, 2017: Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors
  • Feb 28, 2017: Kite Reports Fourth Quarter and Full Year 2016 Financial Results
  • Jan 05, 2017: Kite Pharma appoints new board member
  • Dec 12, 2016: Kite Pharma Announces Publication of T-Cell Therapy Targeting Mutant KRAS in Cancer by the National Cancer Institute (NCI) in New England Journal of Medicine
  • Dec 01, 2016: Kite Pharma appoints senior vice president of supply chain
  • Nov 09, 2016: Kite Pharma Reports Third Quarter 2016 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Kite Pharma Inc, Key Facts
  • Kite Pharma Inc, Key Employees
  • Kite Pharma Inc, Key Employee Biographies
  • Kite Pharma Inc, Major Products and Services
  • Kite Pharma Inc, History
  • Kite Pharma Inc, Subsidiaries
  • Kite Pharma Inc, Joint Venture
  • Kite Pharma Inc, Key Competitors
  • Kite Pharma Inc, Ratios based on current share price
  • Kite Pharma Inc, Annual Ratios
  • Kite Pharma Inc, Annual Ratios (Cont...1)
  • Kite Pharma Inc, Interim Ratios
  • Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Kite Pharma Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Kite Pharma Inc, Performance Chart (2012 - 2016)
  • Kite Pharma Inc, Ratio Charts
  • Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • RegenxBio Inc
  • Kura Oncology Inc
  • Fate Therapeutics Inc
  • Actinium Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll